NRXS
Neuraxis, INC
$7.38
-0.67%
$91.4M
No data for this timeframe.
Vol
Market Cap$91.4M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders3 funds
Inst. Value$687.5K
Inst. Activity1 buys / 0 sells
Insider Activity3B / 0S
Insider Net $$32.0K
SEC Reports6
Press Releases2
Exchange NYSE·Sector Electromedical & Electrotherapeutic Apparatus·Inc. DE·CIK 0001933567·Prev Close $7.43
Recent Activity
May 12, 2026
SEC
NeurAxis reported Q1 2026 revenue of $1.6M (+80% YoY) and EPS of -$0.17, beating consensus estimates of $1.4M and -$0.19
PRESS-RELEASE — Impact 7/10
May 12, 2026
earnings
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
Conference call will be held today, Tuesday, May 12 at 9:00 am ET <pre>Conference call will be held
May 5, 2026
SEC
NeurAxis announced it will report Q1 2026 financial results on May 12, 2026, before market open, with a conference call
PRESS-RELEASE — Impact 2/10
Apr 28, 2026
SEC
Neuraxis filed additional definitive proxy soliciting materials (DEFA14A) amid an apparent dissident/activist campaign.
DEFA14A — Impact 4/10
Apr 28, 2026
Insider
Aharon Gil sold 12,304 shares
Director @ $0.00 ($0.00)
Apr 1, 2026
Insider
Carrico Brian Allen bought 8,060 shares
Chief Executive Officer @ $1.96 ($15.8K)
Apr 1, 2026
Insider
Carrico Thomas Joeseph bought 667 shares
CRO, CCO, CPO @ $1.96 ($1.3K)
Inst.
VANGUARD GROUP INC — DOUBLED
145,562 shares ($660.9K)
Price Targets
$11.00
+49.1% upside
Strong Buy
Current $7.38
Low $9.00
Median $11.00
High $13.00
2 analysts
$9.00
$13.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 20, 2026 | Craig-Hallum | MAINTAIN | Buy → Buy |
| Dec 22, 2025 | Craig-Hallum | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.14 ▲ +15.2% | $-0.14 — $-0.14 | 36% YoY | 1 |
| Next Q | $-0.12 ▼ -4.3% | $-0.12 — $-0.12 | 50% YoY | 1 |
| Current FY | $-0.52 ▲ +3.7% | $-0.52 — $-0.52 | 41% YoY | 1 |
| Next FY | $-0.06 ▼ -200.0% | $-0.06 — $-0.06 | 88% YoY | 1 |
Latest Reports
BULLISH
PRESS-RELEASE
7/10
NeurAxis reported Q1 2026 revenue of $1.6M (+80% YoY) and EPS of -$0.17, beating consensus estimates of $1.4M and -$0.19
May 12, 2026
NEUTRAL
PRESS-RELEASE
2/10
NeurAxis announced it will report Q1 2026 financial results on May 12, 2026, before market open, with a conference call
May 5, 2026
NEUTRAL
Press
3/10
NeurAxis announced a stock dividend on its Series B Preferred Stock, with approximately 510,605 shares of common stock t
Apr 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $660.9K | DOUBLED |
| MORGAN STANLEY | $26.3K | NEW |
| BANK OF AMERICA CORP | $340.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 28, 2026 | Aharon Gil | A | $0.00 |
| Apr 1, 2026 | Carrico Brian | BUY | $15.8K |
| Apr 1, 2026 | Carrico Thomas | BUY | $1.3K |
| Apr 1, 2026 | Henrichs Timothy | BUY | $14.9K |
| Jan 22, 2026 | Aharon Gil | A | $100.0K |
3 institutional holders with $687.5K total value (151,439 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 145,562 | $660.9K | 96.1% | DOUBLED +103.2% |
| 2 | MORGAN STANLEY | 5,802 | $26.3K | 3.8% | NEW |
| 3 | BANK OF AMERICA CORP /DE/ | 75 | $340.00 | 0.0% | DOUBLED +116.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 71,632 | 145,562 | +103.2% | $660.9K | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 27,981 | 71,632 | +156.0% | $220.6K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 31 | 67 | +116.1% | $206.00 | 2025-Q3 |
| MORGAN STANLEY | NEW | — | 5,802 | — | $14.0K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 2,371 | 575 | -75.7% | $1.4K | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 47,094 | 26,821 | -43.0% | $57.7K | 2025-Q1 |
| UBS Group AG | DOUBLED | 1,146 | 2,371 | +106.9% | $5.1K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 47,094 | — | $110.7K | 2024-Q4 |
8 unique insiders with 3 transactions. Net insider value: $32.0K ($32.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Aharon Gil | Director | A | 12,304 | $0.00 | $0.00 |
| Apr 1, 2026 | Carrico Brian Allen | Chief Executive Officer | BUY | 8,060 | $1.96 | $15.8K |
| Apr 1, 2026 | Carrico Thomas Joeseph | CRO, CCO, CPO | BUY | 667 | $1.96 | $1.3K |
| Apr 1, 2026 | Henrichs Timothy Robert | Chief Financial Officer | BUY | 7,593 | $1.96 | $14.9K |
| Jan 22, 2026 | Aharon Gil | Director | A | 21,598 | $4.63 | $100.0K |
| Jan 22, 2026 | Ferge Kristin A | Director | A | 21,598 | $4.63 | $100.0K |
| Jan 22, 2026 | Keyser Jane Elizabeth | Director | A | 21,598 | $4.63 | $100.0K |
| Jan 22, 2026 | Miranda Adrian | CMO, SVP Science & Tech | A | 47,569 | $4.63 | $220.2K |
| Jan 22, 2026 | Watkins Bradley Mitchell | Director | A | 21,598 | $4.63 | $100.0K |
| Jan 22, 2026 | Henrichs Timothy Robert | Chief Financial Officer | A | 75,231 | $4.63 | $348.3K |
| Jan 22, 2026 | Carrico Thomas Joeseph | CRO, CCO, CPO | A | 47,569 | $4.63 | $220.2K |
| Jan 22, 2026 | Carrico Brian Allen | Chief Executive Officer | A | 94,173 | $4.63 | $436.0K |
6 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 4.7/10.
BULLISH
PRESS-RELEASE
7/10
NeurAxis reported Q1 2026 revenue of $1.6M (+80% YoY) and EPS of -$0.17, beating consensus estimates
May 12, 2026
NEUTRAL
PRESS-RELEASE
2/10
NeurAxis announced it will report Q1 2026 financial results on May 12, 2026, before market open, wit
May 5, 2026
NEUTRAL
DEFA14A
4/10
Neuraxis filed additional definitive proxy soliciting materials (DEFA14A) amid an apparent dissident
Apr 28, 2026
BULLISH
8-K
7/10
Neuraxis reported preliminary unaudited Q1 2026 revenue of $1.6M, up 78% YoY from $0.9M, with an ope
Apr 21, 2026
MIXED
424B5
6/10
Neuraxis, Inc. filed a 424B5 prospectus supplement to increase its at-the-market (ATM) offering capa
Apr 21, 2026
NEUTRAL
CLUSTER
2/10
Two Neuraxis executives, including CEO Brian Allen Carrico, purchased shares in the open market, tot
Apr 3, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.00 mean target
+49.1% upside
Strong Buy (3.00)
$9.00 Low
$13.00 High
| Metric | Value |
|---|---|
| Current Price | $7.38 |
| Target Low | $9.00 |
| Target Mean | $11.00 |
| Target Median | $11.00 |
| Target High | $13.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.14 | $-0.14 | $-0.14 | 36.4% | +15.2% | 1↑ 0↓ | $0.0B | 123.7% | 1 |
| Next Q 2026-09-30 |
$-0.12 | $-0.12 | $-0.12 | 50.0% | -4.3% | 0↑ 1↓ | $0.0B | 226.6% | 1 |
| Current FY 2026-12-31 |
$-0.52 | $-0.52 | $-0.52 | 40.8% | +3.7% | 0↑ 1↓ | $0.0B | 169.0% | 1 |
| Next FY 2027-12-31 |
$-0.06 | $-0.06 | $-0.06 | 88.5% | -200.0% | 0↑ 1↓ | $0.0B | 115.6% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.140 | |
| 7d ago | $-0.165 | +0.025 |
| 30d ago | $-0.165 | +0.025 |
| 60d ago | $-0.140 | |
| 90d ago | $-0.140 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 20, 2026 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | Craig-Hallum | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
Conference call will be held today, Tuesday, May 12 at 9:00 am ET <pre>Conference call will be held today, Tuesday, May 12 at 9:00 am ET</pre>
May 12, 2026
earnings_calendar
NRXS Q1 2026 Earnings Scheduled — 2026-05-12
May 5, 2026
earnings
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
<p align="justify">CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical tec
Apr 22, 2026
other
NeurAxis Expands Payer Coverage with Four New Medical Policies
<p align="justify">CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical te
Apr 10, 2026
dividend
NeurAxis, Inc. Announces Preferred Stock Dividend
<p align="justify">CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical t
Mar 20, 2026
earnings_calendar
NRXS Q4 2025 Earnings Scheduled — 2026-03-20
Mar 19, 2026
earnings
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
Conference call will be held today, Thursday, March 19 at 9:00 am ET <pre>Conference call will be held today, Thursday, March 19 at 9:00 am ET</pre>
Mar 19, 2026
earnings_calendar
NRXS Q4 2025 Earnings Scheduled — 2026-03-19